Rare diseases
Investigational molecules
Locations
60 Avenue Rockefeller, 69008 Lyon, France
ENYO Pharma’s clinical research includes studies in Alport syndrome and in participants with impaired renal function, with attention to kidney-related outcomes in settings where renal decline is a major concern.
The sponsor’s renal portfolio is centered on conditions where preservation of glomerular filtration and monitoring of renal tolerability are clinically important.
ENYO Pharma runs clinical trials in conditions such as Alport's syndrome, Renal impairment, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression
FranceStudy on the Effects of Vonafexor, Rosuvastatin Zinc, and Iohexol on Kidney Function in Patients with Impaired Renal Function and Suspected MASH
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
